Drug · Small Molecule

Paclitaxel

CI-DRUG-00000444Explore in graph →NCIt C1411 CHEMBL428647 CIViC Approved

Regulatory

Approvals (39)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory14 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2023-11-21 (see label)	approved	Nov 21, 2023	openfda

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	522	253	562	2,292	39	CA, EU, US	Oct 31, 2001	1988-05
Malignant Breast Neoplasm	Approved	Phase 4	112	45	125	503	3	US	Jan 7, 2005	1994-02
Malignant Lung Neoplasm	Approved	Phase 4	105	46	128	467	3	US	Jan 7, 2005	1994-10
Malignant Pancreatic Neoplasm	Approved	Phase 3	8	5	2	34

Curated evidence

Clinical evidence (35)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–35 of 35 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERCC1 Expression1
Cisplatin + Gemcitabine

Clinical trials

Trials with this intervention (2,327)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 2,327 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02446600	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 3	579	National Cancer Institute (NCI)NIH	4	Sep 29, 2026	clinicaltrials
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Molecule

Record

Kind: Small Molecule
Mechanism: Tubulin inhibitor
Targets: 15 genes
UNII: P88XT4IS4D
Aliases: 10.BETA.,13.ALPHA.- HEXAHYDROXY-, [2aR-[2a Alpha,4beta,4a Beta,6beta,9alpha(alphaR*,betaS*),-11alpha,12alpha,12a Alpha,12b Alpha]]-beta-(benzoylamino)-alpha-hydroxybenzene-propanoic Acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-1a,33,4,-41,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-41,8,-12,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester, [2AR- [2A.ALPHA.,4.BETA.,4A.BETA.,6.BETA.,9.ALPHA.(ALPHA. R*,.BETA.S*),11.ALPHA.,12.ALPHA.,12A.ALPHA.,12B.ALPHA.]]-TAX-11-EN-9-ONE, 4,10-DIACETATE 2- BENZOATE,13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE, 5.BETA.,20-EPOXY-1,2.ALPHA.,4,7.BETA., 5Beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one, 4,10-Diacetate 2-Benzoate 13-Ester With (2R,3S)-N-Benzoyl-3-phenylisoserine, 6,12B-BIS(ACETYL OXY)-12-(BENZOYLOXY)- 2A,3,4,4A,5,6,9,10,11,12,12A,12B,- DODECAHYDRO-4,11- DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO- 7,11-METHANO- 1H-CYCLODECA[3,4]BENZ[1,2-B]OXET-9-YL ESTER, 7 EPI TAXOL, ABI-007, ABRAXANE, AJ-PACLITAXEL, Anzatax, Apealea, APEALEA, Apexelsin, APEXELSIN, APO-PACLITAXEL, Asotax, .BETA.-(BENZOYLAMINO)- .ALPHA.-HYDROXY-, BMS 181339-01, Bristaxol, BRIS TAXOL, CAPXOL, CHEMBL428647, CYCLOPAX, DHP 107, EBETAXEL, EMPAC, ENDOTAG 1, GENAXOL … (+61)

Data updated 12 hours agoSource updated unknown

Identifiers

Codes (45)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code

ERBB2 Overexpression2
Carboplatin + Paclitaxel + TrastuzumabCombination	Endometrial Serous Adenocarcinoma	Predictive	B	Supports Sensitivity Response	4	submitted	EID7386 In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC	civic
Paclitaxel + TrastuzumabCombination	Malignant Salivary Gland NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID6170 Case report of a 61-year-old caucasian male with a renal mass and subsequent liver metastases. Histopathological examination of the liver led to the diagnosis of metastastic adenocarcinoma of the sali… (full text at CIViC) PMID 23826550 · Firwana et al., 2012 · Open in CIViC	civic

RRM1 Underexpression3
Cisplatin + Gemcitabine + PaclitaxelCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	rejected	EID12043 The study began with a total of 443 patients with advanced NSCLC that were randomly assigned to either regimen A (paclitaxel and cisplatin with gemcitabine) or regimen B (cisplatin and vinorelbine). R… (full text at CIViC) PMID 27276561 · Papaemmanuil et al., 2016 · Open in CIViC	civic
Cisplatin + Gemcitabine + PaclitaxelCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12044 The study began with a total of 443 patients with advanced NSCLC that were randomly assigned to either regimen A (paclitaxel and cisplatin with gemcitabine) or regimen B (cisplatin and vinorelbine). R… (full text at CIViC) PMID 23038758 · Vilmar et al., 2013 · Open in CIViC	civic
Gemcitabine + Paclitaxel + VinorelbineSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID5599 The study began with a total of 443 patients that were randomly assigned to either regimen A (Paclitaxel and cisplatin with gemcitabine) or regimen B ( cisplatin and vinorelbine). Of those patients, 2… (full text at CIViC) PMID 23038758 · Vilmar et al., 2013 · Open in CIViC	civic

High2
Carboplatin + Dostarlimab + PaclitaxelCombination	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12341 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 36972026 · Mirza et al., 2023 · Open in CIViC	civic
〃	Malignant Endometrial NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID12343 A phase 3 randomized trial assessed dostarlimab or placebo (combined with carboplatin-paclitaxel) in 494 patients with recurrent or primary advanced (stage III/IV) endometrial cancer (RUBY trial). End… (full text at CIViC) PMID 38866180 · Powell et al., 2024 · Open in CIViC	civic

ATM Underexpression2
Olaparib + PaclitaxelCombination	Malignant Gastric Neoplasm	Predictive	B	Supports Sensitivity Response	1	accepted	EID5215 A randomized phase 2 trial investigating the efficiency of Olaparib plus Paclitaxel vs. Placebo plus Paclitaxel in recurrent or metastatic gastric cancer patients. 123 patients received treatment. Com… (full text at CIViC) PMID 26282658 · Bang et al., 2015 · Open in CIViC	civic
〃	Malignant Gastric Neoplasm	Predictive	B	Does Not Support Sensitivity Response	4	submitted	EID7708 This double-blind, randomized, placebo-controlled, phase 3 study (GOLD) recruited Asian patients with advanced gastric cancer that had progressed after first-line chemotherapy. Patients were randomly … (full text at CIViC) PMID 29103871 · Bang et al., 2017 · Open in CIViC	civic

PTEN Loss2
Buparlisib + Carboplatin + PaclitaxelCombination	Malignant NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID714 All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers. PMID 25672916 · Hyman et al., 2015 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID5957 In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC) PMID 28281183 · Smyth et al., 2017 · Open in CIViC	civic

ATC (WHO)	L01CD01	PACLITAXEL
DIN (Health Canada)	02016796	TAXOL
DIN (Health Canada)	02231605	PACLITAXEL INJECTION
DIN (Health Canada)	02241314	PACLITAXEL
DIN (Health Canada)	02241443	PACLITAXEL INJECTION
DIN (Health Canada)	02241957	PAXENE
DIN (Health Canada)	02243392	TEVA-PACLITAXEL FOR INJECTION
DIN (Health Canada)	02244372	PACLITAXEL FOR INJECTION
DIN (Health Canada)	02248844	APO-PACLITAXEL INJECTABLE
DIN (Health Canada)	02281066	ABRAXANE FOR INJECTABLE SUSPENSION
DIN (Health Canada)	02285363	PACLITAXEL FOR INJECTION
DIN (Health Canada)	02296624	PACLITAXEL FOR INJECTION
DIN (Health Canada)	02320010	PACLITAXEL FOR INJECTION USP
DIN (Health Canada)	02320150	PACLITAXEL INJECTION USP
DIN (Health Canada)	02391465	PACLITAXEL INJECTION USP
DIN (Health Canada)	02408074	PACLITAXEL INJECTION, USP
DIN (Health Canada)	02409712	AJ-PACLITAXEL
DIN (Health Canada)	02496097	PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL
DIN (Health Canada)	02529424	PACLITAXEL INJECTION
DIN (Health Canada)	02536056	PACLITAXEL INJECTION
DPD drug code	101863	PACLITAXEL INJECTION
DPD drug code	102486	PACLITAXEL INJECTION
DPD drug code	14248	TAXOL
DPD drug code	50976	PACLITAXEL INJECTION
DPD drug code	64928	PACLITAXEL
DPD drug code	65079	PACLITAXEL INJECTION
DPD drug code	65627	PAXENE
DPD drug code	67300	TEVA-PACLITAXEL FOR INJECTION
DPD drug code	68340	PACLITAXEL FOR INJECTION
DPD drug code	73215	APO-PACLITAXEL INJECTABLE
DPD drug code	76673	ABRAXANE FOR INJECTABLE SUSPENSION
DPD drug code	77087	PACLITAXEL FOR INJECTION
DPD drug code	78198	PACLITAXEL FOR INJECTION
DPD drug code	80546	PACLITAXEL FOR INJECTION USP
DPD drug code	80560	PACLITAXEL INJECTION USP
DPD drug code	87681	PACLITAXEL INJECTION USP
DPD drug code	89276	PACLITAXEL INJECTION, USP
DPD drug code	89439	AJ-PACLITAXEL
DPD drug code	98597	PACLITAXEL POWDER FOR INJECTABLE SUSPENSION NANOPARTICLE, ALBUMIN-BOUND PACLITAXEL
EMA product	EMEA/H/C/000216	Paxene
EMA product	EMEA/H/C/000778	Abraxane
EMA product	EMEA/H/C/004154	Apealea
EMA product	EMEA/H/C/004441	Pazenir
EMA product	EMEA/H/C/005997	Apexelsin
EMA product	EMEA/H/C/006173	Naveruclif